Immunosuppressive medications

Clinical Journal of the American Society of Nephrology

Volumn 11, Issue 2, 2016, Pages 332-343

  Wiseman, Alexander C ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

Activation; Cell; Cytokines; GN; Immunology; Kidney transplantation

Indexed keywords

ABATACEPT; ALEMTUZUMAB; ATACICEPT; AZATHIOPRINE; BASILIXIMAB; BELATACEPT; BELIMUMAB; BORTEZOMIB; CANAKINUMAB; COMPLEMENT MEMBRANE ATTACK COMPLEX; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; ECULIZUMAB; EPRATUZUMAB; IMMUNOSUPPRESSIVE AGENT; LEFLUNOMIDE; MYCOPHENOLATE MOFETIL; OCRELIZUMAB; OFATUMUMAB; RAPAMYCIN; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RILONACEPT; RITUXIMAB; SECUKINUMAB; TACROLIMUS; TOCILIZUMAB; TOFACITINIB; UNINDEXED DRUG; VELTUZUMAB; MONOCLONAL ANTIBODY;

ACUTE KIDNEY FAILURE; ANTIPROLIFERATIVE ACTIVITY; CELL DIFFERENTIATION; CELL INTERACTION; CELL THERAPY; CLINICAL TRIAL (TOPIC); COMPLEMENT DEPENDENT CYTOTOXICITY; COMPLEMENT INHIBITION; CYTOKINE RELEASE; END STAGE RENAL DISEASE; HEMOLYTIC UREMIC SYNDROME; HUMAN; IMMUNOSTIMULATION; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATORY INFILTRATE; KIDNEY TRANSPLANTATION; NEPHROLOGIST; NONHUMAN; REVIEW; TOXICITY; ADVERSE EFFECTS; ANIMAL; AUTOIMMUNE DISEASES; B LYMPHOCYTE; DRUG EFFECTS; GRAFT REJECTION; GRAFT SURVIVAL; IMMUNOLOGY; KIDNEY DISEASES; MOLECULARLY TARGETED THERAPY; SIGNAL TRANSDUCTION; T LYMPHOCYTE; TREATMENT OUTCOME;

ANIMALS; ANTIBODIES, MONOCLONAL; AUTOIMMUNE DISEASES; B-LYMPHOCYTES; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY DISEASES; KIDNEY TRANSPLANTATION; MOLECULAR TARGETED THERAPY; SIGNAL TRANSDUCTION; T-LYMPHOCYTES; TREATMENT OUTCOME;

EID: 84957080574     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.08570814     Document Type: Review

References (107)

1. Hench PS, Kendall EC, Slocumb CH, Polley HF: The effect of a hormoneof the adrenalcortex (17-hydroxy-11-dehydrocorticosterone: compound E) and of pituitary adrenocorticotropic hormone on rheumatoid arthritis. Ann Rheum Dis 8: 97-104, 1949.
2. Calne RY, Alexandre GP, Murray JE: A study of the effects of drugs in prolonging survival of homologous renal transplants in dogs. Ann N Y Acad Sci 99: 743-761, 1962.
3. Murray JE, Merrill JP, Harrison JH, Wilson RE, Dammin GJ: Prolonged survival of human-kidney homografts by immunosuppressive drug therapy. N Engl J Med 268: 1315-1323, 1963.
4. Zukoski CF, LeeHM,HumeDM: The prolongation of functional survival of canine renal homografts by 6-mercaptopurine. Surg Forum 11: 470-472, 1960.
5. Köhler G, Milstein C: Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256: 495-497, 1975.
6. Borel JF: History of the discovery of cyclosporin and of its early pharmacological development. Wien Klin Wochenschr 114:433-437, 2002.
7. Shimobayashi M, Hall MN: Making new contacts: The mTOR network in metabolism and signalling crosstalk. Nat Rev Mol Cell Biol 15: 155-162, 2014.
8. Ferrer IR, Araki K, Ford ML: Paradoxical aspects of rapamycin immunobiology in transplantation. Am J Transplant 11: 654-659, 2011.
9. Ortho Multicenter Transplant Study Group: A randomized clinical trial of OKT3 monoclonal antibody for acute rejection of cadaveric renal transplants. N Engl J Med 313: 337-342,1985.
10. Herold KC, Hagopian W, Auger JA, Poumian-Ruiz E, Taylor L, Donaldson D, Gitelman SE, Harlan DM, Xu D, Zivin RA, Bluestone JA: Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N Engl J Med 346: 1692-1698, 2002.
11. Keymeulen B, Vandemeulebroucke E, Ziegler AG, Mathieu C, Kaufman L, Hale G, Gorus F, Goldman M,Walter M, Candon S, Schandene L, Crenier L, De Block C, Seigneurin JM, De PauwP, PierardD,Weets I, Rebello P, Bird P, Berrie E, FrewinM, Waldmann H, Bach JF, Pipeleers D, Chatenoud L: Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N Engl J Med 352: 2598-2608, 2005.
12. Flechner SM, Mulgoankar S, Melton LB,Waid TH, Agarwal A, Miller SD, Fokta F, Getts MT, Frederick TJ, Herrman JJ, Puisis JP, O'Toole L, Sung R, Shihab F, Wiseman AC, Getts DR: First-inhuman study of the safety and efficacy of TOL101 induction to prevent kidney transplant rejection. Am J Transplant 14: 1346-1355, 2014.
13. Noble S, Markham A: Cyclosporin. A review of the pharmacokinetic properties, clinical efficacy and tolerability of a microemulsion- based formulation (Neoral). Drugs 50: 924-941,1995.
14. PetersDH, Fitton A, Plosker GL, FauldsD: Tacrolimus. A review of its pharmacology, and therapeutic potential in hepatic and renal transplantation. Drugs 46: 746-794, 1993.
15. Cattran DC, AppelGB,Hebert LA, Hunsicker LG, Pohl MA, Hoy WE, Maxwell DR, Kunis CL; North America Nephrotic Syndrome Study Group: Cyclosporine in patients with steroidresistant membranous nephropathy: A randomized trial. Kidney Int 59: 1484-1490, 2001.
16. Braun N, Schmutzler F, Lange C, Perna A, Remuzzi G, Risler T, Willis NS: Immunosuppressive treatment for focal segmental glomerulosclerosis in adults. Cochrane Database Syst Rev (3): CD003233, 2008.
17. Pirsch JD, Miller J, Deierhoi MH, Vincenti F, Filo RS: A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. FK506 Kidney Transplant Study Group. Transplantation 63: 977-983,1997.
18. Ekberg H, Tedesco-Silva H, Demirbas A, Vítko S, Nashan B, Gü rkan A, Margreiter R, Hugo C, Grinyó JM, Frei U, Vanrenterghem Y, Daloze P, Halloran PF; ELITE-Symphony Study: Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med 357: 2562-2575, 2007.
19. Praga M, Barrio V, Juárez GF, Lu~no J; Grupo Espa~nol de Estudio de la Nefropatía Membranosa: Tacrolimus monotherapy in membranous nephropathy: A randomized controlled trial. Kidney Int 71: 924-930, 2007.
20. Faul C, Donnelly M, Merscher-Gomez S, Chang YH, Franz S, DelfgaauwJ, Chang JM, ChoiHY, Campbell KN, KimK, Reiser J, Mundel P: The actin cytoskeleton of kidney podocytes is a direct target of the antiproteinuric effect of cyclosporine A. Nat Med 14: 931-938, 2008.
21. Naesens M, Kuypers DR, Sarwal M: Calcineurin inhibitor nephrotoxicity. Clin J Am Soc Nephrol 4: 481-508, 2009.
22. Busque S, Cantarovich M, Mulgaonkar S, Gaston R, Gaber AO, Mayo PR, Ling S, Huizinga RB, Meier-Kriesche HU; PROMISE Investigators: The PROMISE study: A phase 2b multicenter study of voclosporin (ISA247) versus tacrolimus in de novo kidney transplantation. Am J Transplant 11: 2675-2684, 2011.
23. Ho ET, Wong G, Craig JC, Chapman JR: Once-daily extendedrelease versus twice-daily standard-release tacrolimus in kidney transplant recipients: A systematic review. Transplantation 95: 1120-1128, 2013.
24. Bunnapradist S, Ciechanowski K, West-Thielke P, Mulgaonkar S, Rostaing L, Vasudev B, Budde K; MELT investigators: Conversion from twice-daily tacrolimus to once-daily extended release tacrolimus (LCPT): The phase III randomized MELT trial. Am J Transplant 13: 760-769, 2013.
25. Maxwell L, Singh JA: Abatacept for rheumatoid arthritis. Cochrane Database Syst Rev 4: CD007277, 2009.
26. Yu CC, Fornoni A,Weins A, Hakroush S,Maiguel D, Sageshima J, Chen L, Ciancio G, Faridi MH, Behr D, Campbell KN, Chang JM, Chen HC, Oh J, Faul C, Arnaout MA, Fiorina P, Gupta V, Greka A, Burke GW 3rd, Mundel P: Abatacept in B7-1-positive proteinuric kidney disease. N Engl J Med 369: 2416-2423,2013.
27. Larsen CP, Pearson TC, Adams AB, Tso P, Shirasugi N, Strobert E, AndersonD, Cowan S, Price K,Naemura J, Emswiler J,Greene J, Turk LA, Bajorath J, Townsend R, Hagerty D, Linsley PS, Peach RJ: Rational development of LEA29Y (belatacept), a highaffinity variant of CTLA4-Ig with potent immunosuppressive properties. Am J Transplant 5: 443-453, 2005.
28. Vincenti F, Charpentier B, Vanrenterghem Y, Rostaing L, Bresnahan B, Darji P, Massari P, Mondragon-Ramirez GA, Agarwal M, Di Russo G, Lin CS, Garg P, Larsen CP: A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study). Am J Transplant 10: 535-546, 2010.
29. Sidiropoulos PI, Boumpas DT: Lessons learned from anti- CD40L treatment in systemic lupus erythematosus patients. Lupus 13: 391-397, 2004.
30. Okimura K, Maeta K, Kobayashi N, Goto M, Kano N, Ishihara T, Ishikawa T, TsumuraH, Ueno A, Miyao Y, Sakuma S, Kinugasa F, Takahashi N, Miura T: Characterization of ASKP1240, a fully human antibody targeting human CD40 with potent immunosuppressive effects. Am J Transplant 14: 1290-1299, 2014.
31. Pescovitz MD: Rituximab, an anti-cd20 monoclonal antibody: History and mechanism of action. Am J Transplant 6: 859-866,2006.
32. Specks U, Merkel PA, Seo P, Spiera R, Langford CA, Hoffman GS, Kallenberg CG, St Clair EW, Fessler BJ, Ding L, Viviano L, Tchao NK, Phippard DJ, Asare AL, Lim N, Ikle D, Jepson B, Brunetta P, Allen NB, Fervenza FC, Geetha D, Keogh K, Kissin EY, Monach PA, Peikert T, Stegeman C, Ytterberg SR,Mueller M, Sejismundo LP, Mieras K, Stone JH; RAVE-ITN Research Group: Efficacy of remission-induction regimens for ANCAassociated vasculitis. N Engl J Med 369: 417-427, 2013.
33. Sinha A, Bagga A: Rituximab therapy in nephrotic syndrome: Implications for patients' management. Nat Rev Nephrol 9:154-169, 2013.
34. Zarkhin V, Li L, Kambham N, Sigdel T, Salvatierra O, Sarwal MM: A randomized, prospective trial of rituximab for acute rejection in pediatric renal transplantation. Am J Transplant 8:2607-2617, 2008.
35. Genovese MC, Kaine JL, Lowenstein MB, Del Giudice J, Baldassare A, Schechtman J, Fudman E, Kohen M, Gujrathi S, Trapp RG, Sweiss NJ, Spaniolo G, Dummer W; ACTION Study Group: Ocrelizumab, a humanized anti-CD20 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: A phase I/II randomized, blinded, placebo-controlled, doseranging study. Arthritis Rheum 58: 2652-2661, 2008.
36. Østergaard M, Baslund B, Rigby W, Rojkovich B, Jorgensen C, Dawes PT,Wiell C,Wallace DJ, Tamer SC, Kastberg H, Petersen J, Sierakowski S: Ofatumumab, a human anti-CD20 monoclonal antibody, for treatment of rheumatoid arthritis with an inadequate response to one or more disease-modifying antirheumatic drugs:Results of a randomized, double-blind, placebocontrolled, phase I/II study. Arthritis Rheum62: 2227-2238, 2010.
37. Martin ST, Cardwell SM, Nailor MD, Gabardi S: Hepatitis B reactivation and rituximab: A new boxed warning and considerations for solid organ transplantation. Am J Transplant 14:788-796, 2014.
38. Wallace DJ, Kalunian K, Petri MA, Strand V, Houssiau FA, Pike M, Kilgallen B, Bongardt S, Barry A, Kelley L, GordonC: Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: Results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study. Ann Rheum Dis 73: 183-190, 2014.
39. Wallace DJ, Gordon C, Strand V, Hobbs K, Petri M, Kalunian K, Houssiau F, Tak PP, IsenbergDA, Kelley L, Kilgallen B, Barry AN, WegenerWA, GoldenbergDM: Efficacy and safety of epratuzumab in patients with moderate/severe flaring systemic lupus erythematosus: Results from two randomized, double-blind, placebo-controlled, multicentre studies (ALLEVIATE) and follow-up. Rheumatology (Oxford) 52: 1313-1322, 2013.
40. Manzi S, Sánchez-Guerrero J, Merrill JT, Furie R, Gladman D, Navarra SV, Ginzler EM, D'Cruz DP, Doria A, Cooper S, Zhong ZJ, Hough D, Freimuth W, Petri MA; BLISS-52 and BLISS-76 StudyGroups: Effects of belimumab, a B lymphocyte stimulatorspecific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: Combined results from two phase III trials. Ann RheumDis 71: 1833-1838, 2012.
41. Dooley MA, Houssiau F, Aranow C, D'Cruz DP, Askanase A, Roth DA, Zhong ZJ, Cooper S, Freimuth WW, Ginzler EM; BLISS-52 and -76 Study Groups: Effect of belimumab treatment on renal outcomes: Results fromthe phase 3 belimumab clinical trials in patients with SLE. Lupus 22: 63-72, 2013.
42. Richez C, Truchetet ME, Schaeverbeke T, Bannwarth B: Atacicept as an investigated therapy for rheumatoid arthritis. Expert Opin Investig Drugs 23: 1285-1294, 2014.
43. Ginzler EM, Wax S, Rajeswaran A, Copt S, Hillson J, Ramos E, Singer NG: Atacicept in combination with MMF and corticosteroids in lupus nephritis: Results of a prematurely terminated trial. Arthritis Res Ther 14: R33, 2012.
44. Cenci S: The proteasome in terminal plasma cell differentiation. Semin Hematol 49: 215-222, 2012.
45. Palumbo A, Anderson K: Multiple myeloma. N Engl J Med 364:1046-1060, 2011.
46. GaballaMR, Laubach JP, Schlossman RL, Redman K, Noonan K, Mitsiades CS, Ghobrial IM, Munshi N, Anderson KC, Richardson PG: Management of myeloma-associated renal dysfunction in the era of novel therapies. Expert Rev Hematol 5: 51-66, quiz 67-68, 2012.
47. Walsh RC, Alloway RR, Girnita AL, Woodle ES: Proteasome inhibitor-based therapy for antibody-mediated rejection. Kidney Int 81: 1067-1074, 2012.
48. PickeringMC,D'Agati VD, Nester CM, Smith RJ, HaasM, Appel GB, Alpers CE, Bajema IM, Bedrosian C, Braun M, Doyle M, Fakhouri F, Fervenza FC, FogoAB, Frémeaux-Bacchi V, GaleDP, Goicoechea de Jorge E, Griffin G, Harris CL, Holers VM, Johnson S, Lavin PJ, Medjeral-Thomas N, Paul Morgan B, Nast CC, Noel LH, Peters DK, Rodríguez de Có rdoba S, Servais A, Sethi S, Song WC, Tamburini P, Thurman JM, Zavros M, Cook HT: C3 glomerulopathy: Consensus report. Kidney Int 84:1079-1089, 2013.
49. ValenzuelaNM,McNamara JT, Reed EF: Antibody-mediated graft injury: Complement-dependent and complement-independent mechanisms. Curr Opin Organ Transplant 19: 33-40, 2014.
50. Bu F, Borsa N, Gianluigi A, Smith RJ: Familial atypical hemolytic uremic syndrome: A review of its genetic and clinical aspects. Clin Dev Immunol 2012: 370426, 2012.
51. Legendre CM, Licht C, Muus P, Greenbaum LA, Babu S, Bedrosian C, Bingham C, Cohen DJ, Delmas Y, Douglas K, Eitner F, Feldkamp T, Fouque D, Furman RR, Gaber O, HertheliusM,Hourmant M, KarpmanD, Lebranchu Y,Mariat C, Menne J, Moulin B, Nürnberger J, Ogawa M, Remuzzi G, Richard T, Sberro-Soussan R, Severino B, Sheerin NS, Trivelli A, Zimmerhackl LB, Goodship T, Loirat C: Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med 368: 2169-2181, 2013.
52. Zuber J, Le Quintrec M, Krid S, Bertoye C, Gueutin V, Lahoche A, Heyne N, Ardissino G, Chatelet V, Noë l LH, Hourmant M, Niaudet P, Frémeaux-Bacchi V, Rondeau E, Legendre C, Loirat C; French Study Group for Atypical HUS: Eculizumab for atypical hemolytic uremic syndrome recurrence in renal transplantation. Am J Transplant 12: 3337-3354, 2012.
53. Stegall MD, Diwan T, Raghavaiah S, Cornell LD, Burns J, Dean PG, Cosio FG, Gandhi MJ, Kremers W, Gloor JM: Terminal complement inhibition decreases antibody-mediated rejection in sensitized renal transplant recipients. Am J Transplant 11:2405-2413, 2011.
54. McCullough JW, Renner B, Thurman JM: The role of the complement system in acute kidney injury. Semin Nephrol 33: 543-556, 2013.
55. Damman J, Daha MR, van Son WJ, Leuvenink HG, Ploeg RJ, SeelenMA: Crosstalk between complement and Toll-like receptor activation in relation to donor brain death and renal ischemiareperfusion injury. Am J Transplant 11: 660-669, 2011.
56. Rhen T, Cidlowski JA: Antiinflammatory action of glucocorticoids- new mechanisms for old drugs. N Engl J Med 353:1711-1723, 2005.
57. Fauci AS, Dale DC, Balow JE: Glucocorticosteroid therapy: Mechanisms of action and clinical considerations. Ann Intern Med 84: 304-315, 1976.
58. Matas AJ: Minimization of steroids in kidney transplantation. Transpl Int 22: 38-48, 2009.
59. Fleischmann R, Kremer J, Cush J, Schulze-Koops H, Connell CA, Bradley JD, Gruben D,Wallenstein GV, Zwillich SH, Kanik KS; ORAL Solo Investigators: Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N Engl J Med 367: 495-507, 2012.
60. Vincenti F, Tedesco Silva H, Busque S, O'Connell P, Friedewald J, Cibrik D, Budde K, Yoshida A, Cohney S,WeimarW, Kim YS, Lawendy N, Lan SP, Kudlacz E, Krishnaswami S, Chan G: Randomized phase 2b trial of tofacitinib (CP-690,550) in de novo kidney transplant patients: Efficacy, renal function and safety at 1 year. Am J Transplant 12: 2446-2456, 2012.
61. Gralla J, Wiseman AC: The impact of IL2ra induction therapy in kidney transplantation using tacrolimus- and mycophenolatebased immunosuppression. Transplantation 90: 639-644, 2010.
62. FeldmannM: Development of anti-TNF therapy for rheumatoid arthritis. Nat Rev Immunol 2: 364-371, 2002.
63. van Schouwenburg PA, Rispens T,WolbinkGJ: Immunogenicity of anti-TNF biologic therapies for rheumatoid arthritis. Nat Rev Rheumatol 9: 164-172, 2013.
64. Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V: Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: Systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 295: 2275-2285, 2006.
65. Dinarello CA, Simon A, van der Meer JW: Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases. Nat Rev Drug Discov 11: 633-652, 2012.
66. Hung AM, Ellis CD, Shintani A, Booker C, Ikizler TA: IL-1b receptor antagonist reduces inflammation in hemodialysis patients. J Am Soc Nephrol 22: 437-442, 2011.
67. Jones SA, Fraser DJ, Fielding CA, Jones GW: Interleukin-6 in renal disease and therapy. Nephrol Dial Transplant 30: 564-574, 2015.
68. Singh JA, Beg S, Lopez-Olivo MA: Tocilizumab for rheumatoid arthritis: A Cochrane systematic review. J Rheumatol 38: 10-20, 2011.
69. Langley RG, Elewski BE, LebwohlM, Reich K, Griffiths CE, Papp K, Puig L, Nakagawa H, Spelman L, Sigurgeirsson B, Rivas E, Tsai TF,WaselN, Tyring S, Salko T,Hampele I,Notter M, Karpov A, Helou S, Papavassilis C; ERASURE Study Group; FIXTURE Study Group: Secukinumab in plaque psoriasis-results of two phase 3 trials. N Engl J Med 371: 326-338, 2014.
70. Solari R, Pease JE, BeggM: "Chemokine receptors as therapeutic targets: why aren't there more drugs?". Eur J Pharmacol 746:363-367, 2015.
71. Haller H, et al.: CCL2 inhibition with emapticap pegol (NOXE36) in type 2 diabetic patients with albuminuria. Presented at the 51st ERA-EDTA Congress, June 1, 2014.
72. Cohen JA, Barkhof F, Comi G, Hartung HP, Khatri BO, Montalban X, Pelletier J, Capra R, Gallo P, Izquierdo G, Tiel- Wilck K, de Vera A, Jin J, Stites T, Wu S, Aradhye S, Kappos L; TRANSFORMS Study Group: Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 362:402-415, 2010.
73. Vincenti F, Mendez R, Pescovitz M, Rajagopalan PR, Wilkinson AH, Butt K, Laskow D, Slakey DP, Lorber MI, Garg JP, Garovoy M: A phase I/II randomized open-label multicenter trial of efalizumab, a humanized anti-CD11a, anti-LFA-1 in renal transplantation. Am J Transplant 7: 1770-1777, 2007.
74. Posselt AM, Bellin MD, Tavakol M, Szot GL, Frassetto LA, Masharani U, Kerlan RK, Fong L, Vincenti FG, Hering BJ, Bluestone JA, Stock PG: Islet transplantation in type 1 diabetics using an immunosuppressive protocol based on the anti-LFA-1 antibody efalizumab. Am J Transplant 10: 1870-1880, 2010.
75. Gupta S, Weinstock-Guttman B: Natalizumab for multiple sclerosis: Appraising risk versus benefit, a seemingly demanding tango. Expert Opin Biol Ther 14: 115-126, 2014.
76. Gelfand EW: Intravenous immune globulin in autoimmune and inflammatory diseases. N Engl J Med 367: 2015-2025, 2012.
77. Jordan SC, Toyoda M, Kahwaji J, Vo AA: Clinical aspects of intravenous immunoglobulin use in solid organ transplant recipients. Am J Transplant 11: 196-202, 2011.
78. Lefaucheur C, Nochy D, Andrade J, Verine J, Gautreau C, Charron D, Hill GS, Glotz D, Suberbielle-Boissel C: Comparison of combination Plasmapheresis/IVIg/anti-CD20 versus high-dose IVIg in the treatment of antibody-mediated rejection. Am J Transplant 9: 1099-1107, 2009.
79. Vo AA, Cam V, Toyoda M, Puliyanda DP, Lukovsky M, Bunnapradist S, Peng A, Yang K, Jordan SC: Safety and adverse events profiles of intravenous gammaglobulin products used for immunomodulation: A single-center experience. Clin J Am Soc Nephrol 1: 844-852, 2006.
80. Zand MS, Vo T, Huggins J, Felgar R, Liesveld J, Pellegrin T, Bozorgzadeh A, Sanz I, Briggs BJ: Polyclonal rabbit antithymocyte globulin triggers B-cell and plasma cell apoptosis by multiple pathways. Transplantation 79: 1507-1515, 2005.
81. Brennan DC, Flavin K, Lowell JA, Howard TK, Shenoy S, Burgess S, Dolan S, Kano JM, Mahon M, Schnitzler MA, Woodward R, Irish W, Singer GG: A randomized, doubleblinded comparison of Thymoglobulin versus Atgam for induction immunosuppressive therapy in adult renal transplant recipients. Transplantation 67: 1011-1018, 1999.
82. Gharekhani A, Entezari-Maleki T, Dashti-Khavidaki S, Khalili H: A review on comparing two commonly used rabbit antithymocyte globulins as induction therapy in solid organ transplantation. Expert Opin Biol Ther 13: 1299-1313, 2013.
83. Büchler M, Hurault de Ligny B, Madec C, Lebranchu Y; French Thymoglobuline Pharmacovigilance Study Group: Induction therapy by anti-thymocyte globulin (rabbit) in renal transplantation: A 1-yr follow-up of safety and efficacy. Clin Transplant 17: 539-545, 2003.
84. Alinari L, Lapalombella R, Andritsos L, Baiocchi RA, Lin TS, Byrd JC: Alemtuzumab (Campath-1H) in the treatment of chronic lymphocytic leukemia. Oncogene 26: 3644-3653,2007.
85. Freedman MS, Kaplan JM, Markovic-Plese S: Insights into the mechanisms of the therapeutic efficacy of alemtuzumab in multiple sclerosis. J Clin Cell Immunol 4: 2013.
86. Hanaway MJ, Woodle ES, Mulgaonkar S, Peddi VR, Kaufman DB, FirstMR,CroyR,Holman J; INTACStudyGroup: Alemtuzumab induction in renal transplantation. N Engl JMed 364: 1909-1919,2011.
87. Kirk AD, Cherikh WS, Ring M, Burke G, Kaufman D, Knechtle SJ, Potdar S, Shapiro R, Dharnidharka VR, Kauffman HM: Dissociation of depletional induction and posttransplant lymphoproliferative disease in kidney recipients treated with alemtuzumab. Am J Transplant 7: 2619-2625, 2007.
88. Peddi VR,Wiseman A, Chavin K, Slakey D: Reviewof combination therapy with mTOR inhibitors and tacrolimus minimization after transplantation. Transplant Rev (Orlando) 27: 97-107, 2013.
89. Walz G, Budde K, Mannaa M, Nü rnberger J, Wanner C, Sommerer C, Kunzendorf U, Banas B, Hörl WH,Obermü ller N, Arns W, Pavenstädt H, Gaedeke J, Büchert M, May C, Gschaidmeier H, Kramer S, Eckardt KU: Everolimus in patients with autosomal dominant polycystic kidney disease. N Engl J Med 363: 830-840, 2010.
90. Serra AL, Poster D, Kistler AD, Krauer F, Raina S, Young J, Rentsch KM, Spanaus KS, Senn O, Kristanto P, Scheffel H, Weishaupt D, Wü thrich RP: Sirolimus and kidney growth in autosomal dominant polycystic kidney disease. N Engl J Med 363: 820-829, 2010.
91. Crespo-Leiro MG, Marzoa-Rivas R, Barge-Caballero E, Paniagua-Martín MJ: Prevention and treatment of coronary artery vasculopathy. Curr Opin Organ Transplant 17: 546-550,2012.
92. Bissler JJ, McCormack FX, Young LR, Elwing JM, Chuck G, Leonard JM, Schmithorst VJ, Laor T, Brody AS, Bean J, Salisbury S, Franz DN: Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. N Engl J Med 358: 140-151, 2008.
93. Baselga J, Campone M, Piccart M, Burris HA 3rd, Rugo HS, Sahmoud T, Noguchi S, Gnant M, Pritchard KI, Lebrun F, Beck JT, Ito Y, Yardley D, Deleu I, Perez A, Bachelot T, Vittori L, Xu Z, Mukhopadhyay P, Lebwohl D, Hortobagyi GN: Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 366: 520-529, 2012.
94. HudesG, CarducciM, Tomczak P, Dutcher J, Figlin R, Kapoor A, Staroslawska E, Sosman J, McDermott D, Bodrogi I, Kovacevic Z, Lesovoy V, Schmidt-Wolf IG, Barbarash O, Gokmen E, O'Toole T, Lustgarten S, Moore L, Motzer RJ;Global ARCC Trial: Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356: 2271-2281, 2007.
95. Elion GB: The purine path to chemotherapy. Science 244: 41-47, 1989.
96. Berns A, Rubenfeld S, Rymzo WT Jr., Calabro JJ: Hazard of combining allopurinol and thiopurine. N Engl J Med 286: 730-731, 1972.
97. Sifontis NM, Coscia LA, Constantinescu S, Lavelanet AF, Moritz MJ, Armenti VT: Pregnancy outcomes in solid organ transplant recipients with exposure to mycophenolate mofetil or sirolimus. Transplantation 82: 1698-1702, 2006.
98. Appel AS, Appel GB: An update on the use of mycophenolate mofetil in lupus nephritis and other primary glomerular diseases. Nat Clin Pract Nephrol 5: 132-142, 2009.
99. Matas AJ, Smith JM, Skeans MA, Thompson B, Gustafson SK, SchnitzlerMA, Stewart DE, CherikhWS,Wainright JL, Snyder JJ, Israni AK, Kasiske BL: OPTN/SRTR 2012 Annual Data Report: Kidney. Am J Transplant 14[Suppl 1]: 11-44, 2014.
100. Kuypers DR, Le Meur Y, Cantarovich M, Tredger MJ, Tett SE, Cattaneo D, Tönshoff B, Holt DW, Chapman J, Gelder T; Transplantation Society (TTS) Consensus Group on TDM of MPA: Consensus report on therapeutic drug monitoring of mycophenolic acid in solid organ transplantation. Clin J Am Soc Nephrol 5: 341-358, 2010.
101. Strand V, Cohen S, Schiff M,Weaver A, Fleischmann R, Cannon G, Fox R, Moreland L, Olsen N, Furst D, Caldwell J, Kaine J, Sharp J, Hurley F, Loew-Friedrich I; Leflunomide Rheumatoid Arthritis Investigators Group: Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Arch Intern Med 159: 2542-2550, 1999.
102. Chacko B, John GT: Leflunomide for cytomegalovirus: Bench to bedside. Transpl Infect Dis 14: 111-120, 2012.
103. ChonWJ, Josephson MA: Leflunomide in renal transplantation. Expert Rev Clin Immunol 7: 273-281, 2011.
104. Hengstler JG, Hengst A, Fuchs J, Tanner B, Pohl J, Oesch F: Induction of DNA crosslinks and DNA strand lesions by cyclophosphamide after activation by cytochrome P450 2B1. Mutat Res 373: 215-223, 1997.
105. Boumpas DT, Austin HA 3rd, Vaughn EM, Klippel JH, Steinberg AD, Yarboro CH, Balow JE: Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet 340: 741-745, 1992.
106. Appel GB, Contreras G, Dooley MA, Ginzler EM, Isenberg D, Jayne D, Li LS, Mysler E, Sánchez-Guerrero J, Solomons N, Wofsy D; Aspreva Lupus Management Study Group: Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol 20: 1103-1112,2009.
107. Stone JH,Merkel PA, Spiera R, Seo P, Langford CA, Hoffman GS, Kallenberg CG, St Clair EW, Turkiewicz A, Tchao NK, Webber L, Ding L, Sejismundo LP, Mieras K, Weitzenkamp D, Ikle D, Seyfert-Margolis V, Mueller M, Brunetta P, Allen NB, Fervenza FC, Geetha D, Keogh KA, Kissin EY, Monach PA, Peikert T, Stegeman C, Ytterberg SR, Specks U; RAVE-ITN Research Group: Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 363: 221-232,2010.